Does Timing Matter in Gene Therapy for nAMD? - Summary - MDSpire

Does Timing Matter in Gene Therapy for nAMD?

Carl C. Awh, MD, FASRS, discusses 2-year phase 2b PRISM results showing durable outcomes with investigational 4D-150 in patients with recently diagnosed neovascular age-related macular degeneration.

  • By

  • Carl C. Awh, MD

  • July 15, 2026

  • 2 min

Share

Objective:

To present the 2-year outcomes of the phase 2b PRISM study on the investigational gene therapy 4D-150 for neovascular age-related macular degeneration (nAMD).

Approach:
  • Study Design: Phase 2b study focusing on patients with recently diagnosed nAMD.
  • Patient Outcomes: Assessment of injection frequency and visual maintenance over 2 years.
Key Findings:
  • 66% of patients went 2 years without additional injections, according to the study results.
  • 87% had far fewer injections compared to standard-of-care aflibercept, as reported in the findings.
  • The majority had 2 or fewer injections over 2 years with maintained vision, based on the study outcomes.
  • The safety profile showed minimal iritis in 2 eyes, treated with topical therapy, as noted in the results.
Interpretation:

Limitations:
  • Study focused on a subgroup of recently diagnosed patients.
  • Long-term follow-up data is limited to 2 years.
Conclusion:

Sources:

Original Source(s)

Does Timing Matter in Gene Therapy for nAMD?

  • by Carl C. Awh, MD

  • July 15, 2026

Related Content

Lessons From the ARCHER Trial

Margaret A. Chang, MD, MS, discusses how findings from the phase 2 ARCHER trial informed the design of the ongoing phase 3 ARCHER II study of vonaprument, which is expected to read out later this year.

Stuart Therapeutics Spotlights Topical RP Program

At OIS Retina, Eric Schlumpf discussed the company’s collagen mimetic peptide platform for retinitis pigmentosa, now in preclinical development.

ORG Detects Retinal Dysfunction Before Structural Changes

At ASRS 2026, Kareem Moussa, MD, presented early data suggesting optoretinography may identify photoreceptor dysfunction in diabetic eyes before conventional imaging reveals abnormalities.